XI Congresso della Società Italiana di Psicopatologia Psichiatria ...

POSTER
The Assessments (Baseline; T1: end of the first week treatment;
T2: end 4-week treatment; T3: end 8-week treatment;
T4: end 12-week treatment; T5: end 18-week treatment; T6:
end 24-week treatment) included besides the YMRS, Psychiatric
Rating Scale (BPRS), the Hamilton Rating Scale for Depression
(HAM-D+ atypical symptoms), the Clinical Global
Impressions Scale for Bipolar Disorder, Modified (CGI-BP-
M), MADRS and the systematic report of adverse events.
Amisulpride was added to other medications, but other antipsychotics.
Results: 36 (88%) patients were responders, 4 (12%) were
non responders.
Amisulpride turned out to be effective and reasonably safe
in the treatment of bipolar mania.
At the end of the first week (T1)of treatment in responders
(reduction of Young Mania Rating Scale > 50%); at endpoint
24-week (T6) treatment amisulpride produced significant
improvements(Total Score) on the YMRS (p = 0.002),
the HAM-D+ atypical symptoms (p = 0.003), mania (p =
0.002), and depression (p = 0.001) subscales of the CGI-BP-
M, MADRS (p = 0.004).
The following assessments confirmed the efficacy of this
drug for manic bipolar.
The most common side effect was sedation (N = 4; 12%),
four females (no responders) galactorrhea, in responder’ s
group some extrapyramidal symptoms and insomnia.
Conclusions: amisulpride is a suitable drug for the treatment
of Manic Bipolar, well tolerated and efficacious in the
acute treatment of Bipolar Disorder I, manic phase.
This study on amisulpride confirms that the drug, D(2) and
D(3) antagonism, may be involved in the mechanisms of the
therapeutic response to antipsychotics in mania.
65. Effectiveness and tolerability
of olanzapine in Bipolar Disorder I,
treatment of bipolar mania: results of a 56week
C. Cimmino, G. Foggia, I. Celentano, G. Barra, M. Romano,
C. Ciliberti, A. Rocco, T. Cante, E. Mauro
Psychiatry Emergency Hospital “San Giovanni di Dio”,
Frattaminore, Napoli
Background: the atypical agent olanzapine has demonstrated
efficacy in bipolar mania in large randomized, controlled
studies, and offers efficacy across a broader range of symptoms
than typical antipsychotics.
Olanzapine has been shown to be effective for manic
episodes as monotherapy and in combination with other
agents such as lithium and divalproex.
Method: this was a clinical study involving 52 subjects suffering
from Bipolar Disorder I, manic phase to a 56-week
treatment with olanzapine (10 mg/day increased to 20 mg
after 3 days of treatment).
The sample of 22 females (F = 48%; mean age 29.3 ± 3.6.)
and 30 males (M = 58%;mean age 32.2 ± 3.2) consecutively
admitted in the Center for the study of Mood Disorders
was recruited in Emergency Psychiatric Hospital with a
DSM-IV TR diagnosis of Bipolar Disorder I, manic phase.
The sample was assessed by Young Mania Rating Scale
(YMRS) total score 20.
The Assessments (Baseline; T1: end of the first week treatment;
T2: end 4-week treatment; T3: end 8-week treatment;
T4: end 12-week treatment; T5: end 18-week treatment; T6:
end 24-week treatment; T7: end 36-week treatment; T8: end
48-week treatment; T9: end 56-week treatment) included
besides the YMRS, Psychiatric Rating Scale (BPRS), the
Hamilton Rating Scale for Depression (HAM-D+ atypical
symptoms), the Clinical Global Impressions Scale for Bipolar
Disorder, Modified (CGI-BP-M), MADRS and the systematic
report of adverse events.
Olanzapine was added to other medications, but other antipsychotics
and other mood stabiliser.
Results: 44 (85%) patients were responders in monotherapy,
8 (15%) were non responders.
Olanzapinés efficacy had been established in the treatment
of bipolar mania.
In this study has been observed effect of olanzapine on mania.
At the end of the first week (T1) of treatment in responders
(reduction of Young Mania Rating Scale > 75%); at endpoint
24-week (T6) treatment olanzapine produced significant
improvements (Total Score) on the YMRS (p = 0.001),
the HAM-D+ atypical symptoms (p = 0.003), mania (p =
0.001), and depression (p = 0.002) subscales of the CGI-BP-
M, MADRS (p = 0.002); at endpoint 56-week (T9) treatment
olanzapine produced significant data for antimanic effect
or for hypomanic relapse absence at Young Mania Rating
Scale (YMRS) total score ≤ 8.2 (p = 0.002), mania (p =
0.001), and depression (p = 0.002) subscales of the CGI-BP-
M, MADRS (p = 0.003)
This study suggested that olanzapine was effective in preventing
manic relapses
(Patients 6, 11.5%). Relapse Data was not significantly in
this sample.
The most common side effect was weight gain (N = 8; 15%).
Dropouts were eight males (no responders).
Conclusions: olanzapine has proven efficacy in acute mania,
some also in bipolar depression and in maintenance
treatment.
In this study there is firm evidence that olanzapine is effective
than a mood stabiliser and tolerated and efficacious in
the acute treatment of Bipolar Disorder I, manic phase.
66. Quetiapine in the treatment
of Personality Disorders (Cluster A and
Cluster B and Cluster C)
C. Cimmino, G. Foggia, I. Celentano, G. Barra, M. Romano
Psychiatry Emergency Hospital, “San Giovanni di Dio”,
Frattaminore, Napoli
There are not many data in the literature regarding quetiapine
use in Cluster A and Cluster B and Cluster C Personality
Disorders.
The objective of this study was to evaluate the efficacy and
safety of quetiapine in treatment Personality Disorders.
This analysis aimed to assess clinical response to quetiapine
treatment in patients with Personality Disorder.
Method: a total of 25 patients diagnosed with personality
disorders (9 patients, 36% Cluster A; 9 patients, 36% Cluster
B; 7 patients, 28% Cluster C) according to DSM-IV TR cri-
254